NCT07165002View on ClinicalTrials.gov

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
HealthyHepatic Insufficiency
Interventions
DRUG

LY3537031

Administered SC

Trial Locations (3)

1010

New Zealand Clinical Research Auckland, Auckland

H-243

Clinical Research Units Hungary, Kistarcsa

831 01

Summit Clinical Research, s.r.o. - Bratislava, Bratislava

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY